IMPA1

Across TCGA pan-cancer cohorts, IMPA1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IMPA1 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IMPA1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IMPA1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where IMPA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	1.000	0.729	.001	36	view →
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	22	view →
LUAD	OS	Median	All	0.906	0.973	.015	6	view →
GBM	OS	Quartile	All	0.249	0.674	.012	5	view →
LSCC	DFS	Median	II,III,IV	0.552	0.798	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IMPA1–PDAC (OS)

Open the PDAC breakdown →